582 related articles for article (PubMed ID: 29976575)
1. IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.
Karakasheva TA; Lin EW; Tang Q; Qiao E; Waldron TJ; Soni M; Klein-Szanto AJ; Sahu V; Basu D; Ohashi S; Baba K; Giaccone ZT; Walker SR; Frank DA; Wileyto EP; Long Q; Dunagin MC; Raj A; Diehl JA; Wong KK; Bass AJ; Rustgi AK
Cancer Res; 2018 Sep; 78(17):4957-4970. PubMed ID: 29976575
[TBL] [Abstract][Full Text] [Related]
2. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
3. Cancer-Associated Fibroblasts Affect Intratumoral CD8
Kato T; Noma K; Ohara T; Kashima H; Katsura Y; Sato H; Komoto S; Katsube R; Ninomiya T; Tazawa H; Shirakawa Y; Fujiwara T
Clin Cancer Res; 2018 Oct; 24(19):4820-4833. PubMed ID: 29921731
[No Abstract] [Full Text] [Related]
4. Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3/AUF1 pathway.
Al-Jomah N; Al-Mohanna FH; Aboussekhra A
Carcinogenesis; 2021 Dec; 42(12):1439-1448. PubMed ID: 34718441
[TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer.
Ham IH; Oh HJ; Jin H; Bae CA; Jeon SM; Choi KS; Son SY; Han SU; Brekken RA; Lee D; Hur H
Mol Cancer; 2019 Mar; 18(1):68. PubMed ID: 30927911
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
[TBL] [Abstract][Full Text] [Related]
7. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.
Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
[TBL] [Abstract][Full Text] [Related]
8. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway.
Wang Y; Jing Y; Ding L; Zhang X; Song Y; Chen S; Zhao X; Huang X; Pu Y; Wang Z; Ni Y; Hu Q
J Exp Clin Cancer Res; 2019 Jun; 38(1):274. PubMed ID: 31234944
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.
Tao L; Huang G; Wang R; Pan Y; He Z; Chu X; Song H; Chen L
Sci Rep; 2016 Dec; 6():38408. PubMed ID: 27922075
[TBL] [Abstract][Full Text] [Related]
10. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway.
Wu X; Tao P; Zhou Q; Li J; Yu Z; Wang X; Li J; Li C; Yan M; Zhu Z; Liu B; Su L
Oncotarget; 2017 Mar; 8(13):20741-20750. PubMed ID: 28186964
[TBL] [Abstract][Full Text] [Related]
11. STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts.
Avalle L; Raggi L; Monteleone E; Savino A; Viavattene D; Statello L; Camperi A; Stabile SA; Salemme V; De Marzo N; Marino F; Guglielmi C; Lobascio A; Zanini C; Forni M; Incarnato D; Defilippi P; Oliviero S; Poli V
Oncogene; 2022 Mar; 41(10):1456-1467. PubMed ID: 35042959
[TBL] [Abstract][Full Text] [Related]
12. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
13. CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma.
Zhang H; Yue J; Jiang Z; Zhou R; Xie R; Xu Y; Wu S
Cell Death Dis; 2017 May; 8(5):e2790. PubMed ID: 28518141
[TBL] [Abstract][Full Text] [Related]
14. Benefits of Multifaceted Chemopreventives in the Suppression of the Oral Squamous Cell Carcinoma (OSCC) Tumorigenic Phenotype.
Mallery SR; Wang D; Santiago B; Pei P; Schwendeman SP; Nieto K; Spinney R; Tong M; Koutras G; Han B; Holpuch A; Lang J
Cancer Prev Res (Phila); 2017 Jan; 10(1):76-88. PubMed ID: 27756753
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblast-derived interleukin-1β activates protumor C-C motif chemokine ligand 22 signaling in head and neck cancer.
Huang YH; Chang CY; Kuo YZ; Fang WY; Kao HY; Tsai ST; Wu LW
Cancer Sci; 2019 Sep; 110(9):2783-2793. PubMed ID: 31325403
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblasts-stimulated interleukin-11 promotes metastasis of gastric cancer cells mediated by upregulation of MUC1.
Wang X; Che X; Liu C; Fan Y; Bai M; Hou K; Shi X; Zhang X; Liu B; Zheng C; Liu Y; Qu X
Exp Cell Res; 2018 Jul; 368(2):184-193. PubMed ID: 29709516
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of interleukin-6 in diagnosis of lung, oral, esophageal, and gall bladder carcinomas.
Vinocha A; Grover RK; Deepak R
J Cancer Res Ther; 2018 Sep; 14(Supplement):S758-S760. PubMed ID: 30249899
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor HIC1 is synergistically compromised by cancer-associated fibroblasts and tumor cells through the IL-6/pSTAT3 axis in breast cancer.
Sun X; Qu Q; Lao Y; Zhang M; Yin X; Zhu H; Wang Y; Yang J; Yi J; Hao M
BMC Cancer; 2019 Dec; 19(1):1180. PubMed ID: 31795965
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.
Putoczki TL; Thiem S; Loving A; Busuttil RA; Wilson NJ; Ziegler PK; Nguyen PM; Preaudet A; Farid R; Edwards KM; Boglev Y; Luwor RB; Jarnicki A; Horst D; Boussioutas A; Heath JK; Sieber OM; Pleines I; Kile BT; Nash A; Greten FR; McKenzie BS; Ernst M
Cancer Cell; 2013 Aug; 24(2):257-71. PubMed ID: 23948300
[TBL] [Abstract][Full Text] [Related]
20. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
